Search

Your search keyword '"Dohner H"' showing total 4 results
Start Over Author "Dohner H" Topic leukemia
4 results on '"Dohner H"'

1. The European LeukemiaNet: achievements and perspectives

Author

Hehlmann, R., Grimwade, D., Simonsson, B., Apperley, J., Baccarani, M., Barbui, T., Barosi, G., Bassan, R., Bene, M. C., Berger, U., Buchner, T., Burnett, A., Cross, N. C. P., De Witte, T. J. M., Dohner, H., Dombret, H., Einsele, H., Engelich, G., Foa, Roberto, Fonatsch, C., Gokbuget, N., Gluckman, E., Gratwohl, A., Guilhot, F., Haferlach, C., Haferlach, T., Hallek, M., Hasford, J., Hochhaus, A., Hoelzer, D., Kiladjian, J. J., Labar, B., Ljungman, P., Mansmann, U., Niederwieser, D., Ossenkoppele, G., Ribera, J. M., Rieder, H., Serve, H., Schrotz King, P., Sanz, M. A., Sauele, S., European Leukemianet For The, Hematology, and CCA - Innovative therapy

Subjects
Gerontology, Economic growth, Biomedical Research, Cooperative research, International Cooperation, Chronic lymphocytic leukemia, Medical Oncology, cooperative leukemia research, cure of leukemia, european leukemianet, leukemia management guidelines, transnational and interdisciplinary cooperation on leukemia, Special Article, European LeukemiaNet, hemic and lymphatic diseases, medicine, Humans, Competence (human resources), Societies, Medical, Leukemia, business.industry, Myelodysplastic syndromes, Translational research Immune Regulation [ONCOL 3], Myeloid leukemia, Hematology, medicine.disease, Minimal residual disease, Europe, european leukemia net, perspectives, business
Abstract

Contains fulltext : 96402.pdf (Publisher’s version ) (Open Access) The only way to cure leukemia is by cooperative research. To optimize research, the European LeukemiaNet integrates 105 national leukemia trial groups and networks, 105 interdisciplinary partner groups and about 1,000 leukemia specialists from 175 institutions. They care for tens of thousands of leukemia patients in 33 countries across Europe. Their ultimate goal is to cure leukemia. Since its inception in 2002, the European LeukemiaNet has steadily expanded and has unified leukemia research across Europe. The European LeukemiaNet grew from two major roots: 1) the German Competence Network on Acute and Chronic Leukemias; and 2) the collaboration of European Investigators on Chronic Myeloid Leukemia. The European LeukemiaNet has improved leukemia research and management across Europe. Its concept has led to funding by the European Commission as a network of excellence. Other sources (European Science Foundation; European LeukemiaNet-Foundation) will take over when the support of the European Commission ends.

Published
2011
Full Text
View/download PDF

2. A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893).

Author

Willemze, R., Suciu, S., Archimbaud, E., Muus, P., Stryckmans, P., Louwagie, E. A., Berneman, Z., Tjean, M., Wijermans, P., Dohner, H., Jehn, U., Labar, B., Jaksic, B., Dardenne, M., and Zittoun, R.

Subjects
ANTINEOPLASTIC agents, ACUTE myeloid leukemia, LYMPHOCYTIC leukemia, MYELOID leukemia, LEUKEMIA treatment, CANCER chemotherapy, LEUKEMIA, HUMAN cytogenetics, PATIENTS
Abstract

5-Aza-2′-deoxycytidine combined with either amsacrine or idarubicin has been applied in a treatment protocol for patients with a relapse of acute myeloid or lymphocytic leukemia. Sixty-three patients received 5-Aza-2′-deoxycytidine 125 mg/m² as a 6 h infusion every 12 h for 6 days in combination with either amsacrine 120 mg/m² as a 1 h infusion on days 6 and 7 (n = 30) or idarubicin 12 mg/m² as a 15 mm infusion on days 5, 6 and 7 (n = 33). Twenty-three patients (36.5%) obtained a complete remission (CR); eight of 30 patients treated with amsacrine and 15 of 33 treated with idarubicin. Patients with an interval of more than 1 year between initial diagnosis and start of the protocol achieved CR in 51.4%, compared to 15.4% for patients with an interval of less than 1 year. Patients with normal cytogenetics had a higher CR rate (61%) than those with abnormal cytogenetic findings (15.8%). Digestive tract and hematologic toxicity was prolonged, compared to standard induction schedules. Median disease-free survival was approximately 8 months, with only 20% of patients staying in remission for more than 1 year. 5-Aza-2′-deoxycytidine is a good antileukernic agent with considerable toxicity. Current results merit further investigations in previously untreated leukemia. [ABSTRACT FROM AUTHOR]

Published
1997

3. Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group

Author

Kirsten Fischer, Barbara Eichhorst, Richard Rosenquist, Hartmut Döhner, Kostas Stamatopoulos, Paolo Ghia, Eugen Tausch, Michael Hallek, Sonia Jaramillo, Valentin Goede, Manuela Hoechstetter, Sandra Robrecht, Andreas Agathangelidis, Johannes Bloehdorn, Christof Schneider, Stephan Stilgenbauer, Jasmin Bahlo, Jaramillo, S., Agathangelidis, A., Schneider, C., Bahlo, J., Robrecht, S., Tausch, E., Bloehdorn, J., Hoechstetter, M., Fischer, K., Eichhorst, B., Goede, V., Hallek, M., Dohner, H., Rosenquist, R., Ghia, P., Stamatopoulos, K., and Stilgenbauer, S.

Subjects
Oncology, medicine.medical_specialty, Chronic lymphocytic leukemia, Article, 03 medical and health sciences, 0302 clinical medicine, International Prognostic Index, Internal medicine, hemic and lymphatic diseases, Medicine, Humans, Chronic Lymphocytic Leukemia, Stereotyped subset, Prospective Studies, Prospective cohort study, Retrospective Studies, business.industry, Retrospective cohort study, Hematology, medicine.disease, Prognosis, Leukemia, Lymphocytic, Chronic, B-Cell, Clinical trial, Leukemia, 030220 oncology & carcinogenesis, Cohort, Mutation, business, IGHV@, Immunoglobulin Heavy Chains, 030215 immunology
Abstract

Almost one-third of all patients with chronic lymphocytic leukemia (CLL) express stereotyped B-cell receptor immunoglobulins (BcR IG) and can be assigned to distinct subsets, each with a particular BcR IG. The largest stereotyped subsets are #1, #2, #4 and #8, associated with specific clinico-biological characteristics and outcomes in retrospective studies. We assessed the associations and prognostic value of these BcR IG in prospective multicenter clinical trials reflective of two different clinical situations: (i) early-stage patients ('watch and wait' arm of the CLL1 trial) (n=592); (ii) patients in need of treatment, enrolled in three phase III trials (CLL8, CLL10, CLL11), treated with different chemo-immunotherapies (n=1,861). Subset #1 was associated with del(11q), higher CLL International Prognostic Index (CLL-IPI) scores and similar clinical course to CLL with unmutated immunoglobulin heavy variable (IGHV) genes (U-CLL) in both early and advanced stage groups. IGHV-mutated (M-CLL) subset #2 cases had shorter time-to-first-treatment (TTFT) versus other M-CLL cases in the early-stage cohort (hazard ratio [HR]: 4.2, confidence interval [CI]: 2-8.6, P

Published
2020

4. Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial

Author

Marco Sborgia, Marco Vignetti, Massimo Breccia, Fabio Efficace, Roberto Cairoli, Hartmut Link, Uwe Platzbecker, Norbert Schmitz, Ombretta Annibali, Agostino Cortelezzi, Francesca Paoloni, Eros Di Bona, Nicola Di Renzo, Alfonso Maria D'Arco, Lorella Melillo, Francesco Lo-Coco, Peter Brossart, Felicetto Ferrara, Chiara Frairia, Franco Mandelli, Christoph Röllig, Laura Cicconi, Claudio Fozza, Konstanze Döhner, Walter Fiedler, Bernd Hertenstein, Francesco Fabbiano, Richard F. Schlenk, Mariadomenica Divona, Francesco Albano, Mohammed Wattad, Maria Teresa Voso, Christian Thiede, Christian Brandts, Paola Fazi, Gerhard Ehninger, Mathias Hänel, Sergio Amadori, Alessandro Rambaldi, Giorgio La Nasa, Helmut R. Salih, Hartmut Döhner, Michael Lübbert, Giuseppe Avvisati, Arnold Ganser, Erika Borlenghi, Cicconi, L, Platzbecker, U, Avvisati, G, Paoloni, F, Thiede, C, Vignetti, M, Fazi, P, Ferrara, F, Divona, M, Albano, F, Efficace, F, Sborgia, M, Di Bona, E, Breccia, M, Borlenghi, E, Cairoli, R, Rambaldi, A, Melillo, L, La Nasa, G, Fiedler, W, Brossart, P, Hertenstein, B, Salih, H, Annibali, O, Wattad, M, Lubbert, M, Brandts, C, Hanel, M, Rollig, C, Schmitz, N, Lin, H, Frairia, C, Fozza, C, Maria D’Arco, A, Di Renzo, N, Cortelezzi, A, Fabbiano, F, Dohner, K, Ganser, A, Dohner, H, Amadori, S, Mandelli, F, Teresa Voso, M, Ehninger, G, Schlenk, R, and Lo-Coco, F

Subjects
Adult, Male, Oncology, Acute promyelocytic leukemia, Cancer Research, medicine.medical_specialty, Adolescent, Retinoic acid, Tretinoin, Follow-Up Studie, law.invention, Young Adult, chemistry.chemical_compound, Leukemia, Promyelocytic, Acute, Randomized controlled trial, law, Germany, Internal medicine, medicine, acute leukemia, Arsenic trioxide, Aged, Antineoplastic Combined Chemotherapy Protocol, business.industry, All trans, Hematology, Long term results, Middle Aged, APL, arsenic trioxide, medicine.disease, Clinical trial, Prospective Studie, Leukemia, Treatment Outcome, Italy, chemistry, Female, business, Settore MED/15 - Malattie del Sangue, Human
Published
2019

Catalog

Books, media, physical & digital resources
See catalog results